Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Heart Failure Specialists (US)(?)

Council Members in this Study Group: 873

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Rohit Arora, MD
Professor of Medicine
Finch University of Health Science-Chicago Medical School

Rohit Arora, MD, FACC, FAHA, FASCI, FACP, is a Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School, Illinois. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Dr. Arora is also Chief of Cardiology at the North...

Hossein Ardehali, MD, PhD, Assistant Professor, Feinberg School of Medicine, Northwestern UniversityHossein Ardehali, MD, PhD
Assistant Professor
Feinberg School of Medicine, Northwestern University

Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...

Dan Streja, MD
Clinical Professor of Medicine
University of California, Los Angeles

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...

Howard Weintraub, MD
Clinical Director
NYU Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Michael Kim, MD
Associate Professor
Feinberg School of Medicine, Northwestern University

Michael Kim, MD, is an Associate Professor at Feinberg School of Medicine, Northwestern University, Illinois. He has served as a Cardiac Electrophysiologist at Health Partners and Regions Hospital in Minnesota and also as an Associate Professor at the University of Minnesota. Dr. Kim has expertise in...

Joshua Feuer, MD
Owner
Joshua M. Feuer, MD

Joshua Feuer, MD, FACC, is a board certified Cardiologist in private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment, and reduction. He has...

Daniel Fisher, MD, FACC, FACP
Cardiologist
NYU Medical Center

Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as...

Daniel Weiss, MD, Chief Medical Officer, Vicor Technologies, Inc.Daniel Weiss, MD
Chief Medical Officer
Vicor Technologies, Inc.

Daniel Weiss, MD, FACC, is a Clinical Cardiac Electrophysiologist with Florida Arrhythmia Consultants and the Founder and President of his own consultancy, Weiss Consulting Groups, which provides consultation services to the business world on medical topics and to medical drug and device startup companies....

View all Leading Experts in this Study Group

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Signs That the Is Party Over? | 10-10-2008
Author: GLG Expert Contributor

The growth of the big pharma companies in the past 20-30 years has to do with the fact that the medical community was willing to accept large trials (some with surrogate endpoints) as proof that a new treatment is good and that it can replace the old one. Since the problems with Troglitazone, Cerivastatin,...

Not All That Shines is Gold | 10-02-2008
Analysis of: Anemia Drugs Linked to Stroke Study Deaths: FDA | health.usnews.com
Author: GLG Expert Contributor

The anemia drug erythropoietin and its congeners have been used extensively in patients with renal failure and in patients with cancer to boost the red cell count. However, erythropoietin also helps reduce programmed cellular death and is involved in the growth of new vessels. Because of these features...

Another reason why government intervention doesn't work | 09-15-2008
Author: GLG Expert Contributor

The Medicare drug system was a political ploy. This just confrims it. The private insurers were unwilling to offer Rx coverage before then because they understood the economics of it.

The trial that is all about hype | 08-28-2008
Author: GLG Expert Contributor

The general public hears the bullet that stents are no better than medications, but the reality that this trial (COURAGE trial) had major flaws, the main being that only 10% of the patients screened participated in the trial. 90% were excluded. Thus, the patients enrolled were not necessarily the typical...

A rough in the diamond | 08-27-2008
Author: GLG Expert Contributor

If truly an association, this will alter the use of this drug.

View All GLG News by members of this Study Group

GLG InstituteSM Seminars with this Study Group's Leading Experts(?)

 

Recent Seminars

GLGi: Lipid Management
Boston, 03-28-2008

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-10-11T13:45:17.197